Cardinal Health Enters into Binding Letter of Intent to Extend Pharmaceutical Distribution Agreements with CVS Health

Impact · against what's priced in

The news is largely neutral for CAH and CVS as it confirms the stability of a major partnership and reaffirms existing guidance. While securing the CVS contract through 2032 reduces renewal risk, the current price for CAH already accepts a sharp deceleration in revenue growth, making the extension a confirmation of the baseline rather than a catalyst.

CAH+0.10

Already priced in

The price assumes

a sharp deceleration in revenue growth, with the price requiring only a 0.9% revenue CAGR